Immunoassays for the quantitation of porcine PAI-1 antigen and activity in biological fluid samples

Thrombosis and Haemostasis

Volumn 84, Issue 6, 2000, Pages 1082-1086

  Leng, H M J ^a   Brouwers, E ^a   Knockaert, I ^a   Declerck, P J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Atherosclerosis; ELISA; Fibrinolysis; PAI 1; Pig

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; ATHEROSCLEROSIS; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SWINE; THROMBOSIS; VALIDATION PROCESS;

EID: 0034533897     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614174     Document Type: Article

References (42)

1. Demonstration of a fast-acting inhibitor of plasminogen activators in plasma
2. Fibrinolysis and its regulation
3. Endothelial plasminogen activator inhibitor (PAI): A new member of the serpin gene family
4. Plasminogen activator inhibitor type-1: Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing
5. Cloning and sequence of a cDNA coding for the human deta-migrating endothelial-cell-type plasminogen activator inhibitor
6. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells
7. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
8. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)
9. Complex formation between plasminogen activator inhibitor 1 and vitronectin in purified systems and in plasma
10. Structure-function relationship in serpins: Current concepts and controversies
11. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type I
12. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding
13. Complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation
14. Bleeding diasthesis due to decreased functional activity of type 1 plasminogen activator
15. Pathophysiology of fibrinolysis
16. Predictive value of fibrinolytic factors in coronary heart disease
17. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
18. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls
19. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque
20. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of plasminogen activator inhibitor type 1-neutralizing monoclonal antibody
21. Introduction to the Leiden Workshop on animal models in Fibrinolysis and Thrombolysis and in vitro alternatives
22. Swine in atherosclerosis research. Development of an experimental animal model and study of the effect of dietary fats on cholesterol metabolism
23. The porcine model for the understanding of thrombogenesis and atherogenesis
24. Atherosclerosis in swine and swine as a model for the study of atherosclerosis
25. Genesis of atherosclerosis in swine fed high fat-high cholesterol diets
26. A noninjury, diet-induced swine model of atherosclerosis for cardiovascular intervention research
27. Regression of advanced atherosclerosis in swine
28. Preparation of monoclonal antibodies: Strategies and procedures
29. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1
30. Peroxidase labelled antibody: A new method of conjugation
31. An immunofunctional assay for active plasminogen activator inhibitor-1 (PAI-1)
32. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases
33. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma
34. Problems of t-PA specific inhibitor determination in human plasma
35. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occulsion and after platelet aggregation
36. Plasminogen activator inhibitor (PAI-1) in plasma and platelets
37. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay
38. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples
39. Immunological quantitation of rabbit plasminogen activator inhibitor-1 in biological samples. Evidence that rabbit platelets do not contain PAI-1
40. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice
41. Presence of active and latent type 1 plasminogen activator inhibitor associated with porcine platelets
42. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi